{
  "table_name": "quant_phosphoproteome_AML_gilteritinib_resistance_pdc_current",
  "table_fullname": "isb-cgc-bq.CPTAC.quant_phosphoproteome_AML_gilteritinib_resistance_pdc_current",
  "column_names": [
    "id_de_cas",
    "id_d_echantillon",
    "id_d_aliquote",
    "id_de_soumission_d_aliquote",
    "id_de_metadonnees_d_execution_d_aliquote",
    "nom_d_etude",
    "abondance_de_proteine_log2ratio",
    "id_refseq",
    "sites_de_phosphorylation"
  ],
  "column_types": [
    "STRING",
    "STRING",
    "STRING",
    "STRING",
    "STRING",
    "STRING",
    "FLOAT64",
    "STRING",
    "STRING"
  ],
  "nested_column_names": [
    "id_de_cas",
    "id_d_echantillon",
    "id_d_aliquote",
    "id_de_soumission_d_aliquote",
    "id_de_metadonnees_d_execution_d_aliquote",
    "nom_d_etude",
    "abondance_de_proteine_log2ratio",
    "id_refseq",
    "sites_de_phosphorylation"
  ],
  "nested_column_types": [
    "STRING",
    "STRING",
    "STRING",
    "STRING",
    "STRING",
    "STRING",
    "FLOAT64",
    "STRING",
    "STRING"
  ],
  "description": [
    "Identifiant unique associé à un patient spécifique (e.g. 24cb0fcb-63d6-11e8-bcf1-0a2705229b82)",
    "Identifiant PDC unique pour cet échantillon (e.g. e8d83eb9-693a-11ea-b1fd-0aad30af8a83)",
    "Identifiant PDC unique pour cet aliquot (e.g. e8db124a-693a-11ea-b1fd-0aad30af8a83)",
    "ID de soumission d'aliquot attribué par le programme (e.g. T14)",
    "Identifie de manière unique l'aliquot en fonction de son utilisation dans l'expérience (en fonction du réactif d'étiquetage et/ou de la répétition biologique)",
    "Nom de l'étude (e.g. Étude pilote sur le cancer du cerveau pédiatrique - Phosphoprotéome)",
    "Rapport log-moyen des ions rapporteurs d'échantillon par rapport à la référence commune des ions de peptides associés au gène dans les acquisitions d'un échantillon biologique spécifique",
    "Identifiant unique donné à une séquence dans la base de données NCBI RefSeq",
    "Codes à lettre unique et positions de séquence de protéine des acides aminés phosphorylés (e.g. t304s310, t59)"
  ],
  "sample_rows": [
    {
      "id_de_cas": "4a4b2172-550c-4dbd-adad-8b3425f3ddea",
      "id_d_echantillon": "baf671ff-e1b6-4cd9-9dfd-5d263db4f5df",
      "id_d_aliquote": "e8cd8b54-b66a-47da-879f-f135582ea0f5",
      "id_de_soumission_d_aliquote": "PTRC_exp12_01",
      "id_de_metadonnees_d_execution_d_aliquote": "85a47ee9-272b-49f0-8f06-eb8ee580eb84",
      "nom_d_etude": "AML Gilteritinib Resistance -  Phosphoproteome",
      "abondance_de_proteine_log2ratio": -0.1025,
      "id_refseq": "NP_001005751.1",
      "sites_de_phosphorylation": "s1075"
    },
    {
      "id_de_cas": "4a4b2172-550c-4dbd-adad-8b3425f3ddea",
      "id_d_echantillon": "baf671ff-e1b6-4cd9-9dfd-5d263db4f5df",
      "id_d_aliquote": "e8cd8b54-b66a-47da-879f-f135582ea0f5",
      "id_de_soumission_d_aliquote": "PTRC_exp12_01",
      "id_de_metadonnees_d_execution_d_aliquote": "85a47ee9-272b-49f0-8f06-eb8ee580eb84",
      "nom_d_etude": "AML Gilteritinib Resistance -  Phosphoproteome",
      "abondance_de_proteine_log2ratio": -0.132,
      "id_refseq": "NP_001005751.1",
      "sites_de_phosphorylation": "s909"
    },
    {
      "id_de_cas": "4a4b2172-550c-4dbd-adad-8b3425f3ddea",
      "id_d_echantillon": "baf671ff-e1b6-4cd9-9dfd-5d263db4f5df",
      "id_d_aliquote": "e8cd8b54-b66a-47da-879f-f135582ea0f5",
      "id_de_soumission_d_aliquote": "PTRC_exp12_01",
      "id_de_metadonnees_d_execution_d_aliquote": "85a47ee9-272b-49f0-8f06-eb8ee580eb84",
      "nom_d_etude": "AML Gilteritinib Resistance -  Phosphoproteome",
      "abondance_de_proteine_log2ratio": 0.1474,
      "id_refseq": "NP_001014436.1",
      "sites_de_phosphorylation": "t291"
    },
    {
      "id_de_cas": "4a4b2172-550c-4dbd-adad-8b3425f3ddea",
      "id_d_echantillon": "baf671ff-e1b6-4cd9-9dfd-5d263db4f5df",
      "id_d_aliquote": "e8cd8b54-b66a-47da-879f-f135582ea0f5",
      "id_de_soumission_d_aliquote": "PTRC_exp12_01",
      "id_de_metadonnees_d_execution_d_aliquote": "85a47ee9-272b-49f0-8f06-eb8ee580eb84",
      "nom_d_etude": "AML Gilteritinib Resistance -  Phosphoproteome",
      "abondance_de_proteine_log2ratio": -0.5073,
      "id_refseq": "NP_001014972.1",
      "sites_de_phosphorylation": "s636"
    },
    {
      "id_de_cas": "4a4b2172-550c-4dbd-adad-8b3425f3ddea",
      "id_d_echantillon": "baf671ff-e1b6-4cd9-9dfd-5d263db4f5df",
      "id_d_aliquote": "e8cd8b54-b66a-47da-879f-f135582ea0f5",
      "id_de_soumission_d_aliquote": "PTRC_exp12_01",
      "id_de_metadonnees_d_execution_d_aliquote": "85a47ee9-272b-49f0-8f06-eb8ee580eb84",
      "nom_d_etude": "AML Gilteritinib Resistance -  Phosphoproteome",
      "abondance_de_proteine_log2ratio": 0.6132,
      "id_refseq": "NP_001025006.1",
      "sites_de_phosphorylation": "s185"
    }
  ]
}